<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacology, dosing, and adverse effects of leflunomide in the treatment of rheumatoid arthritis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacology, dosing, and adverse effects of leflunomide in the treatment of rheumatoid arthritis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pharmacology, dosing, and adverse effects of leflunomide in the treatment of rheumatoid arthritis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert I Fox, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Simon M Helfgott, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">E William St Clair, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">Leflunomide</a> (LEF) is a nonbiological disease-modifying antirheumatic drug (DMARD) that has antiinflammatory and immune modulatory characteristics. LEF is approved by the US Food and Drug Administration (FDA) to treat rheumatoid arthritis (RA). Worldwide, LEF is used as a cost-effective strategy for multiple indications, including psoriatic arthritis and systemic lupus erythematosus [<a href="#rid1">1-3</a>].</p><p>The mechanism of action, pharmacology, dosing, and adverse effects of LEF, particularly in the context of its use in RA, will be reviewed here. The general approach to the management of RA and the use of LEF in the treatment of active disease are presented separately. (See  <a class="medical medical_review" href="/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults"</a> and  <a class="medical medical_review" href="/d/html/7477.html" rel="external">"Alternatives to methotrexate for the initial treatment of rheumatoid arthritis in adults"</a> and  <a class="medical medical_review" href="/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy"</a> and  <a class="medical medical_review" href="/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy"</a>.)</p><p>The use of LEF in other conditions, including psoriatic arthritis, juvenile idiopathic arthritis, dermatomyositis, and systemic lupus erythematosus, and the use of <a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">teriflunomide</a>, its active metabolite, in multiple sclerosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/6428.html" rel="external">"Polyarticular juvenile idiopathic arthritis: Treatment", section on 'Leflunomide'</a> and  <a class="medical medical_review" href="/d/html/4673.html" rel="external">"Arthritis and other musculoskeletal manifestations of systemic lupus erythematosus", section on 'Treatment of arthritis'</a> and  <a class="medical medical_review" href="/d/html/13774.html" rel="external">"Management of refractory cutaneous dermatomyositis in adults", section on 'Other systemic medications'</a> and  <a class="medical medical_review" href="/d/html/143125.html" rel="external">"Clinical use of oral disease-modifying therapies for multiple sclerosis", section on 'Teriflunomide'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">Leflunomide</a> (LEF) is an oral drug that is rapidly absorbed from the gastrointestinal tract; it acts as an immunomodulatory and immunosuppressive agent largely through inhibition of pyrimidine synthesis [<a href="#rid4">4,5</a>].</p><p class="headingAnchor" id="H2501225977"><span class="h2">Inhibition of DHOD and rUMP synthesis</span><span class="headingEndMark"> — </span>LEF is an isoxazole derivative that prevents pyrimidine synthesis. Once absorbed, LEF is converted to its active form (A77-1726), a malononitrilamide known as <a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">teriflunomide</a>  (<a class="graphic graphic_figure graphicRef56364" href="/d/graphic/56364.html" rel="external">figure 1</a>) [<a href="#rid6">6</a>]. The metabolite inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHOD) [<a href="#rid5">5</a>]. The major action of teriflunomide at the doses given for rheumatoid arthritis (RA) is inhibition of the synthesis of a pyrimidine known as ribonucleotide uridine monophosphate pyrimidine (rUMP). This effect is particularly toxic to activated lymphocytes, which depend on de novo synthesis of uridine.</p><p>LEF decreases the synthesis of rUMP through inhibition of the mitochondrial enzyme DHOD. Inhibition of DHOD leads to inability of activated cells to move from G1 to the S phase by activating the p53 pathways of apoptotic selection. This enzyme is essential for the proliferation of T lymphocytes. While additional mechanisms of action have been noted, the inhibition of rUMP synthesis is thought to be the primary mechanism of the antiinflammatory and immunomodulatory effects of LEF at the levels of drug reached in most patients taking the recommended doses [<a href="#rid7">7,8</a>].</p><p>The structure of the enzyme DHOD and the binding site for <a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">teriflunomide</a> have been determined by x-ray crystallography [<a href="#rid9">9</a>]. Human DHOD has two domains: an alpha-helical domain that forms the opening of a channel leading to the active site and an alpha/beta-barrel domain that contains the active site. Teriflunomide binds within the channel of the alpha-helical domain to exert its inhibitory effect on the enzyme.</p><p>Patients with the haplotype DHOD5 have a better response to LEF than patients with other haplotypes [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H2301183157"><span class="h2">Effects on immune cells in vitro</span><span class="headingEndMark"> — </span>LEF impacts many components of the immune-inflammatory response, some of which may be relevant to its mode of action in RA [<a href="#rid4">4,5</a>]. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Inhibition of leukocyte adhesion to vascular endothelial cells [<a href="#rid11">11-16</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preferential inhibitory effects on self-reactive memory B cells [<a href="#rid17">17</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interference with dendritic cell function, disrupting antigen presentation [<a href="#rid18">18</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blocking two steps essential for nuclear factor (NF)-kappa B activation, including degradation of the inhibitor of kappa B alpha and the subsequent translocation of the p65 subunit to the nucleus, blocking the proinflammatory consequences of NF-kappa B activation [<a href="#rid19">19</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhibition of receptor activator of nuclear factor kappa B ligand (RANKL)-mediated osteoclast differentiation [<a href="#rid20">20,21</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhibition of the protein tyrosine kinases Janus kinase (Jak)1 and Jak3, which influence signaling through cytokine receptors [<a href="#rid22">22,23</a>] and of mitogen-activated protein kinase kinase kinase 2 (MAP3K2) [<a href="#rid23">23</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreasing the response to interleukin (IL)-4 by B cells [<a href="#rid24">24-26</a>], inhibiting IL-10 and IL-11 secretion, and reducing IL-2 synthesis [<a href="#rid27">27,28</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increasing synthesis of transforming growth factor (TGF)-beta [<a href="#rid29">29</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Altering the pyrimidine metabolism, leading to a shift from Th1 to Th2 cells [<a href="#rid30">30,31</a>]</p><p></p><p class="headingAnchor" id="H1180929160"><span class="h2">Effects on inflammatory markers in patients</span><span class="headingEndMark"> — </span>Multiple effects on various mediators of inflammation and joint injury have been observed after administration of LEF:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical evidence of antiinflammatory effects of </strong><a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">leflunomide</a> – Findings in a randomized trial involving 38 patients with active RA treated with LEF or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) and using synovial biopsies at baseline and four months revealed similar antiinflammatory effects on cells and molecules involved in joint destruction in both treatment groups [<a href="#rid32">32</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduced numbers of macrophages and T cells</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decreased synovial infiltration of lymphocytes and type I synoviocytes with reduced vascular inflammation, including intracellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) expression, and metalloproteinase production (perhaps decreasing radiographic progression [<a href="#rid33">33</a>])</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the subset of patients fulfilling the 20 percent response criteria of the American College of Rheumatology (ACR20), a more pronounced reduction in the expression of ICAM-1, VCAM-1, IL-1b, and matrix metalloproteinase 1 (MMP-1; collagenase) was found compared with the nonresponders</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Influence on proinflammatory mediators in RA patients</strong> – Differential effects of LEF and MTX have been seen in studies of mediators in patients with RA [<a href="#rid34">34</a>]; LEF reduced serum levels of interferon gamma without a change in IL-6 levels, while both interferon gamma and IL-6 levels were reduced after MTX treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Influences on serum metalloproteinases</strong> – Patients with RA treated with LEF demonstrated decreases in serum levels of MMP-1, the activity of MMP-9, the degradation marker, cartilage oligomeric matrix protein (COMP), and the acute phase protein, serum amyloid A [<a href="#rid35">35</a>].</p><p></p><p>LEF, either directly or through its active metabolite, A771726, inhibits the accumulation of prostaglandin PGE2 at serum concentrations lower than those required to inhibit the induction of cyclooxygenase 2 (COX-2) protein. It does, however, appear unlikely that LEF could be antiinflammatory in vivo by mechanisms that include inhibition of COX-2 or inducible nitric oxide synthase (iNOS) [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H1022594654"><span class="h1">DOSING</span></p><p class="headingAnchor" id="H2980637973"><span class="h2">Administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">Leflunomide</a> (LEF) is available in oral tablets and comes in the following dosages: 10 mg, 20 mg, and 100 mg. LEF is generally administered at 20 mg daily without a loading dose [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H2107689689"><span class="h2">Role of loading dose</span><span class="headingEndMark"> — </span>A loading dose of 100 mg daily for three days was used in some early clinical studies of LEF. However, use of a loading dose is associated with a higher likelihood of side effects, particularly diarrhea and other gastrointestinal disturbances. Thus, one of the authors (RF) and many experts prefer to begin LEF, starting at 20 mg daily, without a loading dose [<a href="#rid38">38,39</a>]. The other author (SH) and some experts prefer to use a loading dose of 100 mg daily for the first three days at the start of therapy or once weekly for three weeks, while taking the regular daily dose on other days in an effort to more quickly reach a therapeutic effect.</p><p>There are very limited data available regarding the relative benefits and risks of a loading dose, although one randomized trial involving a total of 120 patients found no advantage to use of a loading dose (100 mg daily for three days) compared with initiating therapy at a fixed dose (20 mg daily), with adverse events occurring earlier in the loading-dose group [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H321085385"><span class="h2">Ongoing daily dose</span><span class="headingEndMark"> — </span>The usual dose of LEF is 20 mg, administered orally once daily, regardless of whether a loading dose was used. A 10 mg daily dose can be tried in patients with gastrointestinal intolerance of the usual dose, and the lower dose is sometimes used in patients treated with a combination of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) and LEF. (See  <a class="medical medical_review" href="/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy", section on 'Leflunomide'</a>.)</p><p>Limited information is available concerning dosing in patients with kidney function or hepatic impairment. Results of single-dose studies in patients with chronic kidney disease indicate that LEF is not removed by continuous ambulatory peritoneal dialysis or by hemodialysis due to its high degree of protein binding [<a href="#rid40">40,41</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PHARMACOKINETICS, DRUG ELIMINATION, AND GENETIC FACTORS</span></p><p class="headingAnchor" id="H2709062733"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">Leflunomide</a> (LEF) is well absorbed following oral administration. The serum half-life of <a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">teriflunomide</a>, the active metabolite of LEF, is approximately 15 days, but it undergoes extensive enterohepatic recirculation, and plasma levels of this active metabolite above 0.02 mg/L may persist for up to two years. Normally, drug elimination of teriflunomide is achieved through the kidneys and gastrointestinal tract in an approximately equal ratio [<a href="#rid40">40</a>]. Teriflunomide is excreted in the urine as a glucuronide conjugate.</p><p>Drug metabolism is affected by the activity of CYP2C19, a liver enzyme that acts on at least 10 percent of drugs in clinical use, notably <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a>, and <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>. <em>CYP2C19</em> phenotype was associated with cessation due to toxicity, and since CYP2C19 intermediate and poor metabolizers have lower <a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">teriflunomide</a> concentrations, it is likely that they have a particularly poor risk-benefit ratio when using this drug [<a href="#rid42">42</a>].</p><p>Studies in adults have not revealed differences in the pharmacokinetics of the drug based upon gender or age. However, clearance of LEF is increased 38 percent in smokers compared with nonsmokers [<a href="#rid43">43</a>].</p><p>Other genetic factors may influence drug effects. One study has suggested that polymorphisms in the estrogen receptor allele, estrogen receptor 1 (<em>ESR1</em>), may be associated with differences in efficacy among women treated with LEF [<a href="#rid44">44</a>]. Another has suggested that a genetic polymorphism of <em>CYP1A2</em>, but not total or free <a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">teriflunomide</a> concentrations, was associated with increased risk of discontinuing LEF due to side effects in patients with RA [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H2803875512"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span>The metabolic pathways used by LEF affect its interactions with other drugs:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> – LEF has been reported in some patients to potentiate the action of warfarin as a result of its mutual competition at the level of cytochrome metabolism [<a href="#rid46">46,47</a>]. However, both increases and decreases in the effects of warfarin can be seen, and close monitoring is required in patients using both of these agents. (See <a class="local">'Patients receiving vitamin K antagonists'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">Cholestyramine</a> – Elimination of LEF is rapidly increased by this drug, which binds to bile salts and prevents enterohepatic recirculation [<a href="#rid40">40</a>] (see <a class="local">'Treatment to accelerate drug elimination'</a> below).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other agents and cytochrome polymorphisms</strong> – Theoretically, LEF administration in patients with cytochrome 2C9 polymorphisms might alter levels of <a class="drug drug_general" data-topicid="10003" href="/d/drug information/10003.html" rel="external">tolbutamide</a>, <a class="drug drug_general" data-topicid="8492" href="/d/drug information/8492.html" rel="external">glipizide</a>, <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a>, and <a class="drug drug_general" data-topicid="8473" href="/d/drug information/8473.html" rel="external">fluvastatin</a> as it has been noted to cause such changes at higher levels in rodent models [<a href="#rid48">48</a>]. In one study, a genetic polymorphism of CYP1A2 (but not total LEF or <a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">teriflunomide</a> concentrations) predicted adverse reactions and intolerance in patients with RA [<a href="#rid45">45</a>].</p><p></p><p class="headingAnchor" id="H1540158001"><span class="h2">Treatment to accelerate drug elimination</span><span class="headingEndMark"> — </span>Accelerated elimination of the drug (eg, to prevent fetal risk during pregnancy due to potential drug exposure) can be achieved through the administration of <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> (8 g orally three times daily for 11 days) [<a href="#rid7">7</a>]; this is effective because the drug's persistence depends upon enterohepatic circulation of the active metabolite. (See <a class="local">'Pregnancy and lactation'</a> below.)</p><p>This approach can be used if LEF is inappropriately taken during pregnancy, if the patient inadvertently becomes pregnant while taking LEF, or if a women of child-bearing age wishes to become pregnant and if levels persist from prior treatment.</p><p>Serum concentrations &lt;0.02 mg/L should be verified by two separate tests performed at least 14 days apart. If serum concentrations are &gt;0.02 mg/L, additional <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> treatment can be employed.</p><p>As an alternative to <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a>, the Canadian labeling recommends that activated charcoal may be used to enhance drug elimination.</p><p class="headingAnchor" id="H5"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>A range of potential adverse effects may occur in patients using <a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">leflunomide</a> (LEF); major concerns include hypertension, especially in patients on nonsteroidal antiinflammatory drugs (NSAIDs), diarrhea and nausea, hepatotoxicity, and risk of fetal and neonatal toxicity. The risks of LEF use during conception, pregnancy, and lactation are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Leflunomide'</a>.)</p><p>The risk of adverse effects may be affected by specific gene polymorphisms. Observational studies indicate that cytochrome P450 (<em>CYP1A2</em>) and dihydroorotate dehydrogenase (<em>DHODH</em>) gene polymorphisms can influence the risk of adverse effects, but such testing is not available for routine clinical use [<a href="#rid49">49,50</a>]. Adverse effects may also occur due to drug-drug interactions. (See <a class="local">'Drug interactions'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal</strong> – Diarrhea and nausea occur in 10 to 15 percent of patients taking LEF. These side effects are seldom severe enough to lead to drug discontinuation. Diarrhea may be more severe when a loading dose is used [<a href="#rid38">38</a>]. Symptoms usually occur soon after starting therapy but may occur over time with chronic drug use. In rare cases there may be unexplained weight loss [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatic</strong> – Threefold elevation of serum aminotransferases have been noted in up to 13 percent of patients treated with LEF [<a href="#rid7">7,38</a>]. Careful monitoring of LEF has been thought to allow it to be used with a level of safety comparable with that of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) [<a href="#rid52">52</a>]. (See <a class="local">'Warnings and monitoring for liver disease'</a> below.)</p><p></p><p class="bulletIndent1">The changes in liver function are generally reversible with dose reduction or discontinuation of the drug. However, infrequently, hepatoxicity can be severe. Between August 2002 and May 2009, 49 cases of severe liver injury, including 14 cases of fatal liver failure, were reported to the US Food and Drug Administration (FDA) [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1">Most patients who experience transaminase elevation have one or more comorbidities that might contribute to hepatotoxicity, including concomitant NSAID or MTX therapy, previous or concurrent alcohol abuse, nonalcoholic steatohepatitis, or viral or autoimmune hepatitis. The FDA issued a warning based upon these observations [<a href="#rid53">53</a>]. Estimates of the risk of transaminase elevations vary:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one practice-based study in Australia involving 2975 patients with rheumatoid arthritis (RA), the overall incidence of adverse effects was similar among patients receiving MTX alone, LEF alone, or a combination of the two agents [<a href="#rid54">54</a>]. The frequency of patients with abnormal hepatic aminotransferases in these groups was 12, 16, and 19 percent, respectively.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another study of a practice-based cohort of 1953 patients with RA and 151 with psoriatic arthritis found that the risks of elevated hepatic aminotransferase levels above the upper limit of normal were greater with the combination of LEF and MTX compared with monotherapy with either agent or with the use of neither agent (31 percent versus 17 to 22 percent versus 14 percent, respectively) [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent2">Elevations of aminotransferase levels of greater than twice the upper limit of normal occurred in 1 to 2 percent of patients on LEF or MTX alone compared with 5 percent of patients on the combination. The risk appeared to be higher in patients with psoriatic arthritis and in those on higher doses of MTX.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertension</strong> – A small percentage of patients with RA develop hypertension when taking LEF [<a href="#rid56">56,57</a>]. Concurrent therapy with NSAIDs is a risk factor. The proposed mechanism is the displacement of NSAIDs from albumin by <a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">teriflunomide</a>, thereby increasing NSAID activity [<a href="#rid57">57</a>]. Blood pressure monitoring is recommended during the first months of treatment and is also recommended if NSAID therapy is begun at a later date. (See  <a class="medical medical_review" href="/d/html/2385.html" rel="external">"NSAIDs and acetaminophen: Effects on blood pressure and hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary</strong> – LEF treatment has been reported to be associated with an increased risk of interstitial lung disease. However, it is not clear whether this is a true effect or whether this is the result of "channeling bias," in which patients with preexisting interstitial lung disease are more likely to be treated with LEF than MTX, which is known to cause this complication [<a href="#rid58">58</a>]. A 2016 systematic review and meta-analysis of randomized trials failed to demonstrate increased pulmonary toxicity with LEF use [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1">We generally obtain a chest radiograph prior to therapy with LEF and avoid the use of LEF in patients with known interstitial lung disease or a history of MTX-induced lung toxicity. (See  <a class="medical medical_review" href="/d/html/4372.html" rel="external">"Methotrexate-induced lung injury"</a> and  <a class="medical medical_review" href="/d/html/4378.html" rel="external">"Drug-induced lung disease in rheumatoid arthritis", section on 'Leflunomide'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic</strong> – Peripheral neuropathy has been reported in patients receiving LEF [<a href="#rid60">60,61</a>], with partial improvement after drug removal with <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> [<a href="#rid62">62</a>]. A review of 80 cases reported to the FDA noted that symptoms of peripheral nerve dysfunction, typically characterized by axonal polyneuropathy, began a mean of six months after beginning the drug [<a href="#rid63">63</a>]. Discontinuation of LEF within 30 days of the onset of symptoms was associated with a better outcome than discontinuation at a later time. In another study, 5 of 50 RA patients treated with LEF developed symptoms of peripheral neuropathy, but all improved after stopping the drug [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1">Similarly, a case of aseptic meningitis that improved with drug removal has also been reported [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dermatologic</strong> – Rash and alopecia occur in 10 to 15 percent of patients taking LEF. These side effects are typically mild and seldom lead to drug discontinuation. Stevens-Johnson syndrome has been reported in a patient with systemic lupus erythematosus who was receiving LEF [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematologic</strong> – Leukopenia occurs very infrequently; estimates of incidence in patients taking LEF alone ranged from 1 in 3698 to 1 in 4582 patients exposed; for patients also taking MTX, the estimates ranged from 1 in 575 to 1 in 822 [<a href="#rid40">40</a>]. Otherwise, hematologic toxicity primarily results from an interaction between LEF and other drugs. LEF may enhance the bone marrow toxicity of MTX, possibly leading to pancytopenia, agranulocytosis, or thrombocytopenia.</p><p></p><p class="bulletIndent1">LEF can potentiate the anticoagulant effect of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid47">47</a>]. As a result, the international normalized ratio (INR) should be more carefully monitored after initiation of LEF in patients taking warfarin. (See  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects"</a>.)</p><p></p><p>In addition, there was a report in 2010, but not since, of contamination with commercial solvents during the manufacturing process in some generic preparations of LEF used in Asia [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H3691082048"><span class="h1">MONITORING</span></p><p class="headingAnchor" id="H3681297272"><span class="h2">Routine laboratory monitoring</span><span class="headingEndMark"> — </span>In most patients, we obtain the following routine testing during treatment with <a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">leflunomide</a> (LEF): a complete blood count (CBC), aminotransferases, and creatinine every two to four weeks for the first three months or, after increasing the dose, every 8 to 12 weeks for months three to six, then every 12 weeks. (See  <a class="medical medical_review" href="/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Drug monitoring and prevention of drug toxicity'</a>.)</p><p>Closer monitoring is advised in patients receiving <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) and LEF in combination. As an example, we obtain a CBC, creatinine, albumin, and transaminases every two to four weeks for the first three months (or following a dose increase), every four weeks for the next three months, then every three months subsequently. Some experts prefer that patients receiving MTX and LEF concurrently be monitored monthly for at least the first year, then increase the monitoring interval to only every two months [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H3599805797"><span class="h2">Warnings and monitoring for liver disease</span><span class="headingEndMark"> — </span>Patients receiving LEF should be closely monitored for signs of liver disease. LEF can be prescribed in patients with a history of previously abnormal liver function tests (LFTs) from MTX therapy and whose values subsequently normalize. This approach is consistent with the American College of Rheumatology (ACR) recommendations for LEF, which indicate that LEF should not be used in patients with significant prior liver disease suggestive of cirrhosis (Child-Pugh scale A or greater) but allow use in patients with prior elevated LFTs that have returned to normal [<a href="#rid68">68</a>]. Patients with acute or chronic infection with hepatitis B or C should be treated prior to initiating LEF. In patients with hepatitis C who have been treated, caution and close clinical and laboratory follow-up needs to be used after initiation of LEF [<a href="#rid69">69</a>].</p><p>The 2010 US Food and Drug Administration (FDA) warning based upon review of the cases of liver injury described above states [<a href="#rid53">53</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with preexisting liver disease should not receive LEF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with elevated liver enzymes (alanine aminotransferase [ALT] greater than two times the upper limit of normal) should not receive LEF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Caution should be used in patients who are taking other drugs that can cause liver injury.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver enzymes should be monitored at least monthly for three months after starting LEF and at least quarterly thereafter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the ALT rises to greater than two times the upper limit of normal while the patient is on LEF, LEF should be stopped, <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> washout should be begun to speed the removal of LEF from the body, and follow-up LFTs should be conducted at least weekly until the ALT value is within normal range.</p><p></p><p>These FDA recommendations for monitoring frequency are consistent with those of the 2008 ACR recommendations on the use of LEF in rheumatoid arthritis (RA) as well as subsequent ACR guidelines [<a href="#rid68">68,70</a>].</p><p class="headingAnchor" id="H4252372094"><span class="h2">Patients receiving vitamin K antagonists</span><span class="headingEndMark"> — </span>In patients taking <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and related agents, the international normalized ratio (INR) should be more carefully monitored after initiation of LEF because concomitant use of the drugs may affect the INR in either direction. (See <a class="local">'Drug interactions'</a> above and  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">CONTRAINDICATIONS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">Leflunomide</a> (LEF) is contraindicated in pregnant and nursing women and in patients with preexisting liver disease. Live vaccines should not be administered to patients being treated with LEF. (See <a class="local">'Pregnancy and lactation'</a> below and <a class="local">'Adverse effects'</a> above.)</p><p class="headingAnchor" id="H1257958"><span class="h1">PREGNANCY AND LACTATION</span><span class="headingEndMark"> — </span>Women of reproductive potential should not receive therapy until pregnancy has been excluded, they have been counseled concerning fetal risk, and reliable contraceptive measures have been confirmed. Following treatment, pregnancy should be avoided until undetectable serum concentrations (&lt;0.02 mg/L) are verified. However, a report of data from a Canadian registry did not find statistically increased incidence of birth defects or spontaneous abortions in their cohort of 72 pregnancies and births exposed to LEF [<a href="#rid71">71</a>]. Nonetheless, caution remains warranted given the relatively small number of exposed women identified in this study.</p><p>Despite the prolonged half-life of the active metabolite, the drug and its metabolites can be relatively rapidly removed from the body by one of several measures, most commonly use of <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> treatment. (See <a class="local">'Treatment to accelerate drug elimination'</a> above.)</p><p>The risks of <a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">leflunomide</a> (LEF) use during conception, pregnancy, and lactation are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Leflunomide'</a>.)</p><p class="headingAnchor" id="H2402934852"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116127.html" rel="external">"Society guideline links: Rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/512.html" rel="external">"Patient education: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/513.html" rel="external">"Patient education: Rheumatoid arthritis treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/583.html" rel="external">"Patient education: Disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – <a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">Leflunomide</a> (LEF) achieves its antiinflammatory effects through the inhibition of a mitochondrial enzyme termed dihydroorotate dehydrogenase (DHOD), leading to a decrease in the synthesis of ribonucleotide uridine monophosphate pyrimidine (rUMP). (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – A starting dose of 20 mg daily of LEF is appropriate for most patients for whom LEF therapy is indicated. A loading dose is no longer commonly used, as it is associated with an increased risk of gastrointestinal side-effects. In patients with gastrointestinal tolerance, the dose may be lowered to 10 mg daily, with or without the addition of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX). (See <a class="local">'Pharmacokinetics, drug elimination, and genetic factors'</a> above and <a class="local">'Role of loading dose'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – LEF has a side effect profile comparable with that of MTX. Diarrhea and nausea are the most common adverse events. Transaminase elevation occurs in 13 percent of patients and generally reverses with drug cessation. Rash is also commonly observed but generally does not require drug cessation. (See <a class="local">'Pharmacokinetics, drug elimination, and genetic factors'</a> above and <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – We advise monthly monitoring of liver function tests (LFTs) for the first three months of therapy, followed by testing at least every three months when LEF is used as a single agent. In patients who receive LEF in combination with MTX, liver function should be monitored more closely (eg, monthly for at least the first 6 to 12 months). (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy and lactation</strong> – Pregnancy and breast feeding should not be considered until serum concentrations of LEF are undetectable. Because of its long half-life, special measures may be required to eliminate LEF prior to pregnancy. (See <a class="local">'Pregnancy and lactation'</a> above and <a class="local">'Treatment to accelerate drug elimination'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Harigane K, Mochida Y, Shimazaki T, et al. Pharmacoeconomic analysis of biologics and methotrexate for rheumatoid arthritis from the standpoint of the number needed to treat concept under the Japanese health insurance system. Cost Eff Resour Alloc 2022; 20:13.</a></li><li><a class="nounderline abstract_t">Park SK, Park SH, Lee MY, et al. Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea. Clin Ther 2016; 38:2430.</a></li><li><a class="nounderline abstract_t">Chastek BJ, Liu F, Shah N, Harrison DJ. Effect of a tier change policy for biologic disease modifying antirheumatic drugs (DMARDS) on health care cost and medication effectiveness. Value Health 2015; 18:A168.</a></li><li><a class="nounderline abstract_t">Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000; 59:841.</a></li><li><a class="nounderline abstract_t">Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999; 93:198.</a></li><li><a class="nounderline abstract_t">Panek JJ, Jezierska A, Mierzwicki K, et al. Molecular modeling study of leflunomide and its active metabolite analogues. J Chem Inf Model 2005; 45:39.</a></li><li><a class="nounderline abstract_t">Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159:2542.</a></li><li><a class="nounderline abstract_t">Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol Suppl 1998; 53:20.</a></li><li><a class="nounderline abstract_t">Liu S, Neidhardt EA, Grossman TH, et al. Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. Structure 2000; 8:25.</a></li><li><a class="nounderline abstract_t">Wiese MD, Hopkins AM, King C, et al. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2021; 73:983.</a></li><li><a class="nounderline abstract_t">Xu X, Blinder L, Shen J, et al. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. J Immunol 1997; 159:167.</a></li><li><a class="nounderline abstract_t">Dimitrijevic M, Bartlett RR. Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of mononuclear cells in rheumatoid arthritis. Transplant Proc 1996; 28:3086.</a></li><li><a class="nounderline abstract_t">Grisar J, Aringer M, Köller MD, et al. Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells. Ann Rheum Dis 2004; 63:1632.</a></li><li><a class="nounderline abstract_t">Salmi M, Rajala P, Jalkanen S. Homing of mucosal leukocytes to joints. Distinct endothelial ligands in synovium mediate leukocyte-subtype specific adhesion. J Clin Invest 1997; 99:2165.</a></li><li><a class="nounderline abstract_t">Kraan MC, de Koster BM, Elferink JG, et al. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum 2000; 43:1488.</a></li><li><a class="nounderline abstract_t">Dimitrijevic M, Bartlett RR. Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatoid arthritis. Inflamm Res 1996; 45:550.</a></li><li><a class="nounderline abstract_t">Baker D, Marta M, Pryce G, et al. Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine 2017; 16:41.</a></li><li><a class="nounderline abstract_t">Kirsch BM, Zeyda M, Stuhlmeier K, et al. The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function. Arthritis Res Ther 2005; 7:R694.</a></li><li><a class="nounderline abstract_t">Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 1999; 162:2095.</a></li><li><a class="nounderline abstract_t">Urushibara M, Takayanagi H, Koga T, et al. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum 2004; 50:794.</a></li><li><a class="nounderline abstract_t">Kobayashi Y, Ueyama S, Arai Y, et al. The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage. J Bone Miner Metab 2004; 22:318.</a></li><li><a class="nounderline abstract_t">Siemasko K, Chong AS, Jäck HM, et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998; 160:1581.</a></li><li><a class="nounderline abstract_t">Shaw J, Chen B, Wooley P, et al. A novel leflunomide analog, UTL-5b (GBL-5b), suppresses JAK3, MAP3K2, and LITAF genes. Am J Biomed Sci 2011; 3:218.</a></li><li><a class="nounderline abstract_t">Burger D, Begué-Pastor N, Benavent S, et al. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology (Oxford) 2003; 42:89.</a></li><li><a class="nounderline abstract_t">Gilbert C, Levasseur S, Desaulniers P, et al. Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor. J Immunol 2003; 170:5235.</a></li><li><a class="nounderline abstract_t">Stuhlmeier KM. Effects of leflunomide on hyaluronan synthases (HAS): NF-kappa B-independent suppression of IL-1-induced HAS1 transcription by leflunomide. J Immunol 2005; 174:7376.</a></li><li><a class="nounderline abstract_t">Vergne-Salle P, Léger DY, Bertin P, et al. Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes. Cytokine 2005; 31:335.</a></li><li><a class="nounderline abstract_t">Elkayam O, Yaron I, Shirazi I, et al. Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann Rheum Dis 2003; 62:440.</a></li><li><a class="nounderline abstract_t">Cao WW, Kao PN, Aoki Y, et al. A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2. Transplant Proc 1996; 28:3079.</a></li><li><a class="nounderline abstract_t">Fragoso YD, Brooks JB. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Expert Rev Clin Pharmacol 2015; 8:315.</a></li><li><a class="nounderline abstract_t">Dimitrova P, Skapenko A, Herrmann ML, et al. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J Immunol 2002; 169:3392.</a></li><li><a class="nounderline abstract_t">Kraan MC, Reece RJ, Barg EC, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000; 43:1820.</a></li><li><a class="nounderline abstract_t">Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000; 43:495.</a></li><li><a class="nounderline abstract_t">Kraan MC, Smeets TJ, van Loon MJ, et al. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis 2004; 63:1056.</a></li><li><a class="nounderline abstract_t">Kullich WC, Mur E, Aglas F, et al. Inhibitory effects of leflunomide therapy on the activity of matrixmetalloproteinase-9 and the release of cartilage oligomeric matrix protein in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24:155.</a></li><li><a class="nounderline abstract_t">Hamilton LC, Vojnovic I, Warner TD. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. Br J Pharmacol 1999; 127:1589.</a></li><li><a class="nounderline abstract_t">Cutolo M, Bolosiu H, Perdriset G, LEADER Study Group. Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen. Rheumatology (Oxford) 2013; 52:1132.</a></li><li><a class="nounderline abstract_t">Cohen SB, Iqbal I. Leflunomide. Int J Clin Pract 2003; 57:115.</a></li><li><a class="nounderline abstract_t">Osiri M, Shea B, Robinson V, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2003; :CD002047.</a></li><li><a class="nounderline abstract_t">Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002; 41:421.</a></li><li><a class="nounderline abstract_t">Bergner R, Peters L, Schmitt V, Löffler C. Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. Clin Rheumatol 2013; 32:267.</a></li><li><a class="nounderline abstract_t">Wiese MD, Schnabl M, O'Doherty C, et al. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Res Ther 2012; 14:R163.</a></li><li><a class="nounderline abstract_t">Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999; 58:1137.</a></li><li><a class="nounderline abstract_t">Dziedziejko V, Kurzawski M, Safranow K, et al. The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 2011; 12:41.</a></li><li><a class="nounderline abstract_t">Hopkins AM, Wiese MD, Proudman SM, et al. Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. Br J Clin Pharmacol 2016; 81:113.</a></li><li><a class="nounderline abstract_t">Chonlahan J, Halloran MA, Hammonds A. Leflunomide and warfarin interaction: case report and review of the literature. Pharmacotherapy 2006; 26:868.</a></li><li><a class="nounderline abstract_t">Lim V, Pande I. Leflunomide can potentiate the anticoagulant effect of warfarin. BMJ 2002; 325:1333.</a></li><li><a class="nounderline abstract_t">Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77:1.</a></li><li><a class="nounderline abstract_t">Bohanec Grabar P, Rozman B, Tomsic M, et al. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008; 64:871.</a></li><li><a class="nounderline abstract_t">Grabar PB, Rozman B, Logar D, et al. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68:1367.</a></li><li><a class="nounderline abstract_t">Coblyn JS, Shadick N, Helfgott S. Leflunomide-associated weight loss in rheumatoid arthritis. Arthritis Rheum 2001; 44:1048.</a></li><li><a class="nounderline abstract_t">van Roon EN, Jansen TL, Houtman NM, et al. Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf 2004; 27:345.</a></li><li class="breakAll">FDA Drug Safety Communication: New boxed warning for severe liver injury with arthritis drug Arava (leflunomide) www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm218679.htm (Accessed on July 15, 2010).</li><li><a class="nounderline abstract_t">Bird P, Griffiths H, Tymms K, et al. The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis. J Rheumatol 2013; 40:228.</a></li><li><a class="nounderline abstract_t">Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010; 69:43.</a></li><li><a class="nounderline abstract_t">Nurmohamed MT, van Halm VP, Dijkmans BA. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. Drugs 2002; 62:1599.</a></li><li><a class="nounderline abstract_t">Rozman B, Praprotnik S, Logar D, et al. Leflunomide and hypertension. Ann Rheum Dis 2002; 61:567.</a></li><li><a class="nounderline abstract_t">Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006; 54:1435.</a></li><li><a class="nounderline abstract_t">Conway R, Low C, Coughlan RJ, et al. Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials. J Rheumatol 2016; 43:855.</a></li><li><a class="nounderline abstract_t">Bharadwaj A, Haroon N. Peripheral neuropathy in patients on leflunomide. Rheumatology (Oxford) 2004; 43:934.</a></li><li><a class="nounderline abstract_t">Kho LK, Kermode AG. Leflunomide-induced peripheral neuropathy. J Clin Neurosci 2007; 14:179.</a></li><li><a class="nounderline abstract_t">Negi A, Rhys-Dillon C, Camilleri JP. A case of distal renal tubular acidosis (type 1) presenting with musculoskeletal pain. Rheumatology (Oxford) 2004; 43:809.</a></li><li><a class="nounderline abstract_t">Bonnel RA, Graham DJ. Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther 2004; 75:580.</a></li><li><a class="nounderline abstract_t">Cohen JD, Jorgensen C, Sany J. Leflunomide-induced aseptic meningitis. Joint Bone Spine 2004; 71:243.</a></li><li><a class="nounderline abstract_t">Rincón-Riaño DN, Fernández-Ávila DG, Gutiérrez JM. Leflunomide-induced Stevens Johnson syndrome in a patient with systemic lupus erythematosus. Rev Colomb Reumatol 2017; 24:242.</a></li><li><a class="nounderline abstract_t">Li J, Huang H, Zhang H. Detection of residual solvents in leflunomide by GC. Northwest Pharmaceutical Journal 2010; 1:003.</a></li><li class="breakAll">Reports of Leflunomide Hepatotoxicity in Patients with Rheumatoid Arthritis. http://www.rheumatology.org/publications/hotline/0801leflunomide.asp (Accessed on January 10, 2013).</li><li><a class="nounderline abstract_t">Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762.</a></li><li><a class="nounderline abstract_t">Sebastiani M, Milazzo L, Atzeni F, et al. Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis. Mod Rheumatol 2019; 29:895.</a></li><li><a class="nounderline abstract_t">Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2016; 68:1.</a></li><li><a class="nounderline abstract_t">Bérard A, Zhao JP, Shui I, Colilla S. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. Ann Rheum Dis 2018; 77:500.</a></li></ol></div><div id="topicVersionRevision">Topic 7515 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35331233" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pharmacoeconomic analysis of biologics and methotrexate for rheumatoid arthritis from the standpoint of the number needed to treat concept under the Japanese health insurance system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27771177" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effect of a tier change policy for biologic disease modifying antirheumatic drugs (DMARDS) on health care cost and medication effectiveness</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11053058" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Leflunomide: mode of action in the treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10600330" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Mechanism of action for leflunomide in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15667127" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Molecular modeling study of leflunomide and its active metabolite analogues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10573044" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9666414" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mechanism of action of leflunomide in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673429" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32339392" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9200452" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8962195" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of mononuclear cells in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15547088" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9151788" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Homing of mucosal leukocytes to joints. Distinct endothelial ligands in synovium mediate leukocyte-subtype specific adhesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10902750" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8951506" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28161400" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15899055" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9973483" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15022321" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15221489" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9469413" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A novel leflunomide analog, UTL-5b (GBL-5b), suppresses JAK3, MAP3K2, and LITAF genes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12509619" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12734372" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15905585" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effects of leflunomide on hyaluronan synthases (HAS): NF-kappa B-independent suppression of IL-1-induced HAS1 transcription by leflunomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16099671" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12695157" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8962191" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25712857" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12218161" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10943872" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10728741" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15115713" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16762150" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Inhibitory effects of leflunomide therapy on the activity of matrixmetalloproteinase-9 and the release of cartilage oligomeric matrix protein in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10455314" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23401601" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12661795" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Leflunomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12535423" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Leflunomide for treating rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12074690" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical pharmacokinetics of leflunomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23179005" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22784880" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10651393" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Leflunomide: a review of its use in active rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21174621" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26331989" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16716139" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Leflunomide and warfarin interaction: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12468482" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Leflunomide can potentiate the anticoagulant effect of warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15637526" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical consequences of cytochrome P450 2C9 polymorphisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18496682" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19605743" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11352235" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Leflunomide-associated weight loss in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15061688" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15061688" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23322457" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19147616" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12109923" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12006342" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Leflunomide and hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16645972" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980577" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15213340" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Peripheral neuropathy in patients on leflunomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17107800" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Leflunomide-induced peripheral neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15163835" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A case of distal renal tubular acidosis (type 1) presenting with musculoskeletal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15179412" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Peripheral neuropathy in patients treated with leflunomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15182800" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Leflunomide-induced aseptic meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Leflunomide-induced Stevens Johnson syndrome in a patient with systemic lupus erythematosus</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Detection of residual solvents in leflunomide by GC</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Detection of residual solvents in leflunomide by GC</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18512708" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30582388" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26545825" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29222350" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
